The Business Interests Bankrolling Andrew Cuomo's Run for Mayor
A quarter-million dollars came from the head of Suffolk Construction, a Boston-based builder betting big on a New York City expansion.
Another $150,000 arrived from the chairman of Vornado Realty Trust, who is searching for a way to revive a stalled Midtown Manhattan redevelopment so important that he once called it his 'promised land.'
DoorDash, the food delivery service lobbying City Hall on regulations that could disrupt its business model, chipped in a staggering $1 million.
The donations make up just a fraction of the checks from New York business leaders, billionaires and special interest groups pouring into a super PAC boosting Andrew M. Cuomo, the favorite in the Democratic primary for mayor on June 24.
With $10 million raised so far, the super PAC, Fix the City, is already the single largest outside spending force in New York City's political history, surpassing a record set in 2021. It has spent multiples more on ads than any campaign in the race, blanketing New Yorkers' screens in paeans to the former governor.
The next biggest candidate super PAC, set up to back Assemblyman Zohran Mamdani, a democratic socialist who is second in recent polls, has 1/50th of the funds.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Podcast Bro Theo Von Questions How 'America First' Trump Really Is Amid Potential Iran War
Popular podcast host Theo Von joined Democratic Rep. Ro Khanna (Calif.) Friday in taking a hard stance against potential U.S. involvement in the Israel-Iran conflict. Khanna appeared on Von's podcast 'This Past Weekend' to discuss several topics, from foreign affairs to AI. At one point in the segment, Khanna promoted the War Powers Resolution, a bipartisan bill he introduced with Republican Rep. Thomas Massie (Ky.) aimed at prohibiting U.S. armed forces from unauthorized hostilities in Iran. During his discussion with Von, Khanna noted several people in MAGA's base who have been vocal about the U.S. not going to war with Iran, including Tucker Carlson and Rep. Marjorie Taylor Greene (Ga.). Von agreed with the two conservatives, stating, 'this is a horrible idea.' 'Yeah, people say, 'Well, you don't know a ton about the Middle East.' Like, that's fine. I don't want people I know, my friends, getting called up. I don't want the children of my friends getting called over to die,' Von said. 'I don't even understand how it's an option.' Von, who had Donald Trump on his podcast last year, helped the president reach younger male voters during the 2024 presidential election. Khanna remarked on the influence of Von's interview with Trump, stating the podcaster made the president 'the most human that I've actually seen him,' after the two opened up about the president's brother, alcoholism and cocaine. Last month, Von performed a controversial comedy act at a military base in Qatar before Trump addressed U.S. and Qatari troops. The podcast host has seemingly gotten closer to the Trump family, even having dinner with Ivanka and her husband, Jared Kushner, after they attended his comedy show in Miami. Miami looked good on you @TheoVon ! Come back and visit us soon !😎 — Ivanka Trump (@IvankaTrump) May 14, 2025 Now, however, Von is beginning to question the 'America First' claims that Trump made during his campaign. When Khanna asked Von if he knew anyone who was supporting the idea of the U.S. going to war with Iran, Von responded, 'Nobody.' I asked @TheoVon if he knows anyone who says we should go to war with Nobody. I feel like it was supposed to be America first. — Ro Khanna (@RoKhanna) June 20, 2025 Von went on to tell Khanna that 'it feels like we are just working for Israel,' and that he believes a lot of Americans are beginning to feel 'disillusioned' by U.S. leaders. 'I felt like it was supposed to be America first, like, we're focusing on, like, 'What are we doing to get things back into America,' right? To like, increase like the purpose of being an American, to refill our hearts with blood and ... make us feel something again here, and make us be excited about being an American,' Von said. JD Vance Tells Theo Von Musk Made A 'Huge Mistake' Going After Trump Exclusive: Israel Seeks Swift Action On Iran, Sources Say, With A Split U.S. Administration Trump Says He Should've Gotten 5 Nobel Peace Prizes While Continuing To Weigh Iran Strikes
Yahoo
18 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
